AR113805A1 - Composiciones y métodos para tratar cáncer hepático - Google Patents

Composiciones y métodos para tratar cáncer hepático

Info

Publication number
AR113805A1
AR113805A1 ARP180103133A ARP180103133A AR113805A1 AR 113805 A1 AR113805 A1 AR 113805A1 AR P180103133 A ARP180103133 A AR P180103133A AR P180103133 A ARP180103133 A AR P180103133A AR 113805 A1 AR113805 A1 AR 113805A1
Authority
AR
Argentina
Prior art keywords
compositions
methods
liver cancer
treat liver
pembrolizumab
Prior art date
Application number
ARP180103133A
Other languages
English (en)
Inventor
Michael Kevin Wolf
Swaminathan Murugappan
Jennifer Lorraine Gansert
Original Assignee
Merck Sharp & Dohme
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Amgen Inc filed Critical Merck Sharp & Dohme
Publication of AR113805A1 publication Critical patent/AR113805A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/844—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Se proporcionan métodos y composiciones para tratar los cánceres hepáticos primarios y/o los cánceres hepáticos secundarios que usan una combinación de talimogene laherparepvec y pembrolizumab, una variante de pembrolizumab o fragmento de unión a antígeno de los mismos.
ARP180103133A 2017-10-27 2018-10-26 Composiciones y métodos para tratar cáncer hepático AR113805A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762578071P 2017-10-27 2017-10-27

Publications (1)

Publication Number Publication Date
AR113805A1 true AR113805A1 (es) 2020-06-10

Family

ID=64453576

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103133A AR113805A1 (es) 2017-10-27 2018-10-26 Composiciones y métodos para tratar cáncer hepático

Country Status (13)

Country Link
US (1) US20200353022A1 (es)
EP (1) EP3700544A1 (es)
JP (1) JP2021501150A (es)
KR (1) KR20200078483A (es)
CN (1) CN111278448A (es)
AR (1) AR113805A1 (es)
AU (1) AU2018355519A1 (es)
BR (1) BR112020007494A2 (es)
CA (1) CA3075294A1 (es)
MX (1) MX2020003388A (es)
SG (1) SG11202002123XA (es)
TW (1) TWI817958B (es)
WO (1) WO2019084418A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2170959B1 (en) 2007-06-18 2013-10-02 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
US20210008135A1 (en) * 2017-04-28 2021-01-14 Merck Sharp & Dohme Corp. Biomarkers for cancer therapeutics

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU2695101A (en) 2000-01-21 2001-07-31 Biovex Ltd Virus strains
EP2170959B1 (en) 2007-06-18 2013-10-02 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
PT2691112T (pt) 2011-03-31 2018-07-10 Merck Sharp & Dohme Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados
EA201590451A1 (ru) 2012-08-30 2016-05-31 Эмджен Инк. Способ лечения меланомы с применением вируса простого герпеса и ингибитора иммунной контрольной точки
CA2955084C (en) * 2014-07-16 2023-08-29 Transgene Sa Combination of oncolytic virus with immune checkpoint modulators
HUE045108T2 (hu) * 2014-07-16 2019-12-30 Transgene Sa Onkolitikus vírus immunellenõrzõpont-modulátorok expresszálására
AU2016271018A1 (en) 2015-05-29 2017-11-30 Dynavax Technologies Corporation Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer
CN108778301A (zh) * 2016-03-10 2018-11-09 永恒生物科技股份有限公司 通过联合疗法来治疗实体瘤或淋巴瘤的方法
KR20190112263A (ko) * 2016-12-12 2019-10-04 멀티비르 인코포레이티드 암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물
US20210008135A1 (en) * 2017-04-28 2021-01-14 Merck Sharp & Dohme Corp. Biomarkers for cancer therapeutics

Also Published As

Publication number Publication date
AU2018355519A1 (en) 2020-03-26
RU2020111709A3 (es) 2022-04-26
WO2019084418A1 (en) 2019-05-02
EP3700544A1 (en) 2020-09-02
US20200353022A1 (en) 2020-11-12
RU2020111709A (ru) 2021-11-29
TW201922273A (zh) 2019-06-16
BR112020007494A2 (pt) 2020-11-03
KR20200078483A (ko) 2020-07-01
JP2021501150A (ja) 2021-01-14
CA3075294A1 (en) 2019-05-02
CN111278448A (zh) 2020-06-12
MX2020003388A (es) 2020-08-03
TWI817958B (zh) 2023-10-11
SG11202002123XA (en) 2020-04-29

Similar Documents

Publication Publication Date Title
ECSP18040250A (es) Composiciones y métodos para inhibir la actividad arginasa
CO2017012342A2 (es) Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit)
CO2017010618A2 (es) Anticuerpos contra icos
EP4302835A3 (en) Methods of treating ovarian cancer
AU2017348322A8 (en) Compositions and methods for treating EZH2-mediated cancer
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
BR112017023821A2 (pt) moduladores de k-ras
BR112017017700A2 (pt) métodos, composições e kits para tratamento do câncer
PE20170680A1 (es) Tratamientos conjuntos con anticuerpos anti cd40
PH12017501879A1 (en) Methods for treating cancer
CO2017003005A2 (es) Anticuerpos anti-mfi2
CO2019000753A2 (es) Métodos para tratar el cáncer de próstata
CO2021002954A2 (es) Anticuerpos anti-αvβ8 y composiciones y usos de los mismos
MX2020006297A (es) Variantes de cd19.
PH12018501943A1 (en) Pharmaceutical compositions for the treatment of cancer
DK3478284T3 (da) Forbindelser og sammensætninger til behandling af cancer
CO2022009696A2 (es) Anticuerpo anti-lilrb1 y usos del mismo
PH12017501880A1 (en) Methods for treating cancer
IL268163A (en) Methods, compositions, and kits for treatment of cancer
BR112018005331A2 (pt) inibidores de pcna
AR113805A1 (es) Composiciones y métodos para tratar cáncer hepático
BR112018013928A2 (pt) composições terapêuticas e métodos para tratamento da hepatite b
EA201691896A1 (ru) Соединения и способы их применения
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
MX2019003311A (es) Metodos para tratamiento de cancer de ovario.

Legal Events

Date Code Title Description
FB Suspension of granting procedure